Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Aug 02, 2016
Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
16% Increase in Revenue; 12% Increase in Tests Delivered
13% Growth with Record Number of Prostate Cancer Tests Delivered
More than 20% Increase in Both International Revenue and Tests Delivered
Launched Oncotype SEQ™ Liquid Biopsy Test and Announced Collaboration to Commercialize Epic Sciences' AR-V7 Test
Conference Call Today at 4:30 p.m. ET
Jul 26, 2016
Genomic Health to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 2, 2016
REDWOOD CITY, Calif. , July 26, 2016 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 2 at 4:30 p.m. Eastern Time to discuss its second quarter 2016 financial results.  The call and webcast will follow
Jul 07, 2016
Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer
Validation Study Led by Memorial Sloan Kettering Cancer Center, Published in JAMA Oncology, Demonstrated Patients with AR-V7 Positive Circulating Tumor Cells Have Significantly Better Outcomes if Treated with Chemotherapy versus Hormonal Treatments
Jun 14, 2016
Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel
Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey
Jun 08, 2016
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival
Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival
Jun 05, 2016
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients
Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women
Oral Presentation Highlights Positive Impact Oncotype DX Has on Decision Making Process, Including in Node-positive Disease
May 31, 2016
Genomic Health to Present at Jefferies 2016 Healthcare Conference
REDWOOD CITY, Calif. , May 31, 2016 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on Tuesday, June 7, 2016 at
May 26, 2016
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions
May 25, 2016
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy
May 04, 2016
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
19% Increase in Revenue; 16% Increase in Tests Delivered
Unparalleled Prospective Outcomes Evidence Drives Further Growth in U.S. Invasive Breast Business; 16% Increase in Revenue and 11% Increase in Test Volume
Conference Call Today at 4:30 p.m. ET